673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

• Vijay Kasturi,
• Robert Haddad,
• Julie E Bauman,
• Martin Birkhofer

Affiliations

Vijay Kasturi

Aff14 0000 0004 0412 6436grid.467308.eEMD Serono Inc Rockland MA USA

Robert Haddad

Aff3 grid.65499.370000000121069910Dana Farber Cancer Institute Boston MA USA

Julie E Bauman

6George Washington University, Washington, DC, USA

Martin Birkhofer

3AVEO Oncology, Boston, MA, USA